Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 4/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30792894 | 0.88 | KMT2A (0.48) | MDM4TP53 | |
| SCHEMBL17446719 | 0.87 | PTPN1 (0.48) | PTPN1HDAC1HDAC2CTSSCTSL | |
| SCHEMBL29480443 | 0.86 | CTSK (0.58) | PTPN1CTSSCTSLCTSBCTSK | |
| SCHEMBL17446669 | 0.84 | HDAC1 (0.49) | PTPN1HDAC1HDAC2TNF | |
| SCHEMBL17446822 | 0.83 | PTPN1 (0.45) | PTPN1HDAC1HDAC2TNFMDM4 | |
| SCHEMBL30385094 | 0.82 | PTPN1 (0.59) | PTPN1HDAC1HDAC2TNF | |
| SCHEMBL24235686 | 0.82 | PTPN1 (0.54) | PTPN1HDAC1HDAC2TNF | |
| SCHEMBL23463497 | 0.82 | TNF (0.51) | PTPN1HDAC1HDAC2TNFMDM4 | |
| SCHEMBL12493153 | 0.81 | MDM4 (0.57) | MDM4TP53 | |
| SCHEMBL119859 | 0.81 | MDM4 (0.57) | MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261639-A1 | TRIAZOLE-BASED AMINOGLYCOSIDE-PEPTIDE CONJUGATES AND METHODS OF USE | UNIVERSITY OF MANITOBA (CA) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261639-A1 | TRIAZOLE-BASED AMINOGLYCOSIDE-PEPTIDE CONJUGATES AND METHODS OF USE | NRDC, ANPEP, DNPEP | PTPN1 3688/4885HDAC1 1746/4885HDAC2 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.